Drug intelligence / Profile preview

beclomethasone dipropionate + olodaterol

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Inhalation

Overview

This appears to be a theoretical combination of beclomethasone dipropionate (an inhaled corticosteroid) and olodaterol (a long-acting beta-agonist). However, based on available information, this specific combination does not exist as an approved or marketed product. Beclomethasone dipropionate is commonly combined with formoterol, while olodaterol is combined with tiotropium.

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on beclomethasone dipropionate + olodaterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beclomethasone dipropionate + olodaterol.

Explore the full profile